Latest News
Category: ASX
First Patient in Australia Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Telix today announces the first commercial dose in Australia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11...
Read more
First Patient Enrolled in ProstACT TARGET Study
Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s...
Read more
Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent...
Read more
Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment
Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC)...
Read more
Telix Half-Year Results 2022 and Shareholder Update
Telix is pleased to present the Company’s financial results for the half-year ending 30 June 2022, together with a shareholder...
Read more
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
Telix today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of...
Read more
Telix 1H 2022 Financial Results and Company Update Investor Call
Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August...
Read more
APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of...
Read more
Activities Report and Appendix 4C for June 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June...
Read more